Business Context and Reporting Period
This Form 6-K/A filing by GlaxoSmithKline plc covers the period ending February 2015. The document serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMR) under the GlaxoSmithKline 2009 Performance Share Plan (PSP). The transactions were executed to meet tax liabilities following the vesting of awards.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to specific share transaction prices:
- Ordinary Share Price: £15.4312 per share (transaction date: February 13, 2015).
- American Depositary Share (ADS) Price: $46.21 per ADS (transaction date: February 11, 2015).
Material Changes
The filing details changes in shareholdings for specific executives due to tax withholding. There are no reported material changes to the company's business operations, financial position, or strategic direction in this document.
Guidance, Outlook, and Risks
This filing contains no management commentary, forward-looking guidance, outlook, risk factors, or discussion of contingencies. It is strictly a regulatory disclosure of insider trading activity compliant with Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Type: Sales of Ordinary Shares and withholding of ADSs were conducted solely to satisfy tax obligations upon the vesting of performance share awards.
- Executive Involvement: Executive Directors Sir Andrew Witty and Mr. S. Dingemans were among those selling shares to meet tax liabilities.
- Volume of Transactions: A total of 78,661 Ordinary Shares were sold by various PDMRs, and 6,858 ADSs were withheld by two individuals.
- Notification Date: The Company and relevant parties were advised of these transactions on February 17, 2015.